Expand Expand| Cat.No. : | Kit-1713 |
| Product Overview : | B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit T cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host"s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer. |
| Size : | 96 reactions |
| Description : | The CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, B7-2 is coated on a 96-well plate. Next, CTLA4-biotin is incubated with B7-2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader. |
| Applications : | This kit is useful for screening for inhibitors of CTLA4 binding to B7-2. |
| Storage : | Stable at least 6 months from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival |
| Kit Components : | CTLA4 (CD152), Fc fusion, Biotin-labeled: 3 µg; -80°C B7-2 (CD86), Fc fusion: 10 µg; -80°C Streptavidin-HRP: 15 µl; +4°C 3x CTLA4 Assay Buffer: 50 ml; -20°C Blocking Buffer: 50 ml; +4°C HRP chemiluminescent substrate A (transparent bottle): 6 ml; +4°C HRP chemiluminescent substrate B (brown bottle): 6 ml; +4°C White 96-well microplate: 1; +4°C |
Welcome! For price inquiries, please feel free to contact us through the form below. We will get back to you as soon as possible.
Download Datasheet
See All CTLA4 Related Kits
Download Datasheet